MX2022010218A - Anticuerpo anti-il-2 y fragmento de union a antigeno del mismo y su uso medico. - Google Patents

Anticuerpo anti-il-2 y fragmento de union a antigeno del mismo y su uso medico.

Info

Publication number
MX2022010218A
MX2022010218A MX2022010218A MX2022010218A MX2022010218A MX 2022010218 A MX2022010218 A MX 2022010218A MX 2022010218 A MX2022010218 A MX 2022010218A MX 2022010218 A MX2022010218 A MX 2022010218A MX 2022010218 A MX2022010218 A MX 2022010218A
Authority
MX
Mexico
Prior art keywords
antigen
antibody
binding fragment
medical use
complex
Prior art date
Application number
MX2022010218A
Other languages
English (en)
Inventor
Yuan Lin
Cheng Liao
Fuxiang Zhu
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of MX2022010218A publication Critical patent/MX2022010218A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona un anticuerpo anti-IL-2, un fragmento de unión a antígeno del mismo y el uso médico del mismo. También se proporciona un complejo (que incluye una proteína de fusión) del anticuerpo anti-IL-2, su fragmento de unión a antígeno e IL-2, y el uso del complejo como fármaco para tratar enfermedades autoinmunes y enfermedades inflamatorias.
MX2022010218A 2020-02-21 2021-02-19 Anticuerpo anti-il-2 y fragmento de union a antigeno del mismo y su uso medico. MX2022010218A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010107662 2020-02-21
PCT/CN2021/076806 WO2021164722A1 (zh) 2020-02-21 2021-02-19 抗il-2抗体、其抗原结合片段及其医药用途

Publications (1)

Publication Number Publication Date
MX2022010218A true MX2022010218A (es) 2022-09-19

Family

ID=77390419

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010218A MX2022010218A (es) 2020-02-21 2021-02-19 Anticuerpo anti-il-2 y fragmento de union a antigeno del mismo y su uso medico.

Country Status (11)

Country Link
US (1) US20230089620A1 (es)
EP (1) EP4108683A4 (es)
JP (1) JP2023515480A (es)
KR (1) KR20220143869A (es)
CN (1) CN115210257A (es)
AU (1) AU2021223063A1 (es)
BR (1) BR112022016326A2 (es)
CA (1) CA3169980A1 (es)
MX (1) MX2022010218A (es)
TW (1) TW202140563A (es)
WO (1) WO2021164722A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115850471A (zh) * 2022-10-13 2023-03-28 深圳市百士通科技开发有限公司 一种抗人il-2单克隆抗体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
PL1644412T5 (pl) 2003-07-01 2019-01-31 Ucb Biopharma Sprl Modyfikowane fragmenty Fab przeciwciała
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
CN104004088B (zh) 2007-09-26 2017-11-07 Ucb医药有限公司 双特异性抗体融合物
PL2334705T3 (pl) 2008-09-26 2017-06-30 Ucb Biopharma Sprl Produkty biologiczne
WO2014028748A1 (en) * 2012-08-15 2014-02-20 Irm Llc Interleukin 2 antibodies and antibody complexes
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
US10138298B2 (en) * 2015-10-23 2018-11-27 The Regents Of The University Of California Anti-IL-2 antibodies and compositions and uses thereof
KR102687530B1 (ko) * 2016-05-04 2024-07-25 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
WO2019168791A2 (en) * 2018-02-28 2019-09-06 The Board Of Trustees Of The Leland Stanford Junior University Single-chain il-2/antibody fusions that selectively activate regulatory t cells

Also Published As

Publication number Publication date
EP4108683A4 (en) 2024-04-03
CA3169980A1 (en) 2021-08-26
WO2021164722A1 (zh) 2021-08-26
JP2023515480A (ja) 2023-04-13
EP4108683A1 (en) 2022-12-28
AU2021223063A1 (en) 2022-09-29
BR112022016326A2 (pt) 2022-10-11
CN115210257A (zh) 2022-10-18
TW202140563A (zh) 2021-11-01
US20230089620A1 (en) 2023-03-23
KR20220143869A (ko) 2022-10-25

Similar Documents

Publication Publication Date Title
CA3010621A1 (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
SA520411202B1 (ar) مترافقات سيتوكين لعلاج أمراض المناعة الذاتية
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
MX2021000083A (es) Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.
MX2020010144A (es) Dosificación subcutánea de anticuerpos anti grupo de diferenciación 38 (cd38).
MX2020012905A (es) Proteínas de unión multiespecíficas y mejoras con estas.
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
MX2022003930A (es) Conjugados de péptido de camptotecina.
MX2021001143A (es) Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo.
MX2022003306A (es) Inmunocitoquina que comprende un complejo de proteina heterodimerico basado en il-15/il-15ra y su uso.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
WO2020132658A3 (en) Tubulysins and protein-tubulysin conjugates
ZA202003320B (en) Glucuronylation as acidic post-translational modification on therapeutic monoclonal antibodies
WO2019234694A3 (en) Therapeutic methods using antibody drug conjugates (adcs)
MX2020006171A (es) Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
MX2023014389A (es) Anticuerpos anti-sirp-alfa.
CO2021001410A2 (es) Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso
CL2022003715A1 (es) Tubulisinas y conjugados de proteinas-tubulisina
MX2022010218A (es) Anticuerpo anti-il-2 y fragmento de union a antigeno del mismo y su uso medico.
MX2023009681A (es) Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon.
ZA202309150B (en) Antibody against nkp46 and application of antibody
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
MX2021008919A (es) Dosis y administracion de anticuerpos anti-c5 para el tratamiento del sindrome uremico hemolitico atipico (shua).
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof
MX2021010254A (es) Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos.